Cardiovascular Events with Finerenone in Kidney Disease and Type 2 Diabetes | NEJM
Potassium management with finerenone: Practical aspects - Wanner - 2022 - Endocrinology, Diabetes & Metabolism - Wiley Online Library
Missouri Society of Health-System Pharmacists - CE: Nonsteroidal Mineralcorticoid Receptor Antagonists in Diabetic Kidney Disease
Finerenone in Predominantly Advanced CKD and Type 2 Diabetes With or Without Sodium-Glucose Cotransporter-2 Inhibitor Therapy - ScienceDirect
A randomized controlled study of finerenone vs. eplerenone in patients with worsening chronic heart failure and diabetes mellitu
Clinical Overview: Finerenone for Chronic Kidney Disease Associated With Type 2 Diabetes
Non‐steroidal mineralocorticoid receptor antagonism for the treatment of cardiovascular and renal disease - Bramlage - 2016 - European Journal of Heart Failure - Wiley Online Library
Safety and dosing of KERENDIA® (finerenone) tablets HCP
PDF) Finerenone Dose–Exposure–Serum Potassium Response Analysis of FIDELIO-DKD Phase III: The Role of Dosing, Titration, and Inclusion Criteria
Finerenone Reduces New-Onset Atrial Fibrillation in Patients With Chronic Kidney Disease and Type 2 Diabetes - ScienceDirect
Finerenone|Cas# 1050477-31-0
Missouri Society of Health-System Pharmacists - CE: Nonsteroidal Mineralcorticoid Receptor Antagonists in Diabetic Kidney Disease
Fong Voon Ken on Twitter: "4/ Initiation and dose adjustment of finerenone according to the eGFR and potassium level. Use of novel hypokalemic agents like zirconium and patiromer would be useful to
How Finerenone Compares to Other Mineralocorticoid Receptor Antagonists
Finerenone - Wikipedia
Finerenone - wikidoc
Finerenone Dose–Exposure–Serum Potassium Response Analysis of FIDELIO-DKD Phase III: The Role of Dosing, Titration, and Inclusion Criteria | SpringerLink
Frontiers | Cardiovascular-renal protective effect and molecular mechanism of finerenone in type 2 diabetic mellitus
Finerenone in patients with chronic kidney disease and type 2 diabetes with and without heart failure: a prespecified subgroup analysis of the FIDELIO‐DKD trial - Filippatos - 2022 - European Journal of
Mineralocorticoid Receptor Antagonism in Chronic Kidney Disease
Edgar V. Lerma 🇵🇭 on Twitter: "Finerenone dose adjustments in CKD #ISNWCN 🇲🇾 #Nephpearls https://t.co/iwHSOpFVLH" / Twitter
Daily Medication Pearl: Finerenone (Kerendia)
Finerenone dosing based on estimated glomerular filtration rate (eGFR)... | Download Scientific Diagram
Finerenone in chronic kidney disease | Nature Reviews Nephrology
Frontiers | Mineralocorticoid Receptor Antagonists in Diabetic Kidney Disease
